Skip to content
Brand AI

Deciphera Pharmaceuticals

Recent events

Recent events tied to this brand in public sources.

Back to profile1 entries

  1. 2020

    FDA approves Qinlock for advanced GIST

    The FDA approved Deciphera Pharmaceuticals’ ripretinib (Qinlock) for fourth-line treatment of advanced gastrointestinal stromal tumors in adults previously treated with three or more kinase inhibitor therapies, including imatinib.

    Source